Jonathan Sackner-Bernstein

Summary

Publications

  1. ncbi request reprint Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy
    Jonathan Sackner-Bernstein
    Clin Cardiol 28:I19-27. 2005
  2. doi request reprint Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart F
    James E Udelson
    Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Card Fail 15:385-93. 2009
  3. ncbi request reprint Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure
    Jonathan D Sackner-Bernstein
    Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, NY 11030, USA
    Circulation 111:1487-91. 2005
  4. ncbi request reprint Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure
    Jonathan D Sackner-Bernstein
    Clinical Scholars Program, Division of Cardiology, 1st Floor Cohen, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030, USA
    Curr Cardiol Rep 7:204-10. 2005
  5. ncbi request reprint Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials
    Jonathan D Sackner-Bernstein
    Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, NY 11030, USA
    JAMA 293:1900-5. 2005
  6. ncbi request reprint Increasing organ transplantation--fairly
    Jonathan D Sackner-Bernstein
    Division of Cardiology, North Shore University Hospital, Manhasset, NY 11030, USA
    Transplantation 77:157-9. 2004
  7. ncbi request reprint Neurohormonal antagonism in heart failure: what is the optimal strategy?
    Jonathan D Sackner-Bernstein
    Division of Cardiology, St Luke s Roosevelt Hospital, New York, NY, USA
    Mt Sinai J Med 71:115-26. 2004
  8. ncbi request reprint Practical guidelines to optimize effectiveness of beta-blockade in patients postinfarction and in those with chronic heart failure
    Jonathan D Sackner-Bernstein
    Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, New York 11030, USA
    Am J Cardiol 93:69B-73B. 2004
  9. ncbi request reprint Nesiritide for acute decompensated heart failure: does the benefit justify the risk?
    Jonathan Sackner-Bernstein
    Clinilabs, Inc, 423 West 55th Street, 4th Floor, New York, NY 10019, USA
    Curr Cardiol Rep 9:187-93. 2007
  10. ncbi request reprint Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure
    Paul J Hauptman
    Division of Cardiology, Saint Louis University School of Medicine, St Louis, Missouri, USA
    Am J Cardiol 98:60L-66L. 2006

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy
    Jonathan Sackner-Bernstein
    Clin Cardiol 28:I19-27. 2005
    ....
  2. doi request reprint Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart F
    James E Udelson
    Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Card Fail 15:385-93. 2009
    ....
  3. ncbi request reprint Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure
    Jonathan D Sackner-Bernstein
    Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, NY 11030, USA
    Circulation 111:1487-91. 2005
    ..Renal function is an important prognostic factor for patients with acutely decompensated heart failure (ADHF). We investigated the renal effects of nesiritide as treatment for ADHF...
  4. ncbi request reprint Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure
    Jonathan D Sackner-Bernstein
    Clinical Scholars Program, Division of Cardiology, 1st Floor Cohen, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030, USA
    Curr Cardiol Rep 7:204-10. 2005
    ..Patients refractory to diuretic therapy may be considered for treatment with inotropes or vasodilators, and others may be considered for venovenous ultrafiltration. The rationale for use of each therapy is reviewed...
  5. ncbi request reprint Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials
    Jonathan D Sackner-Bernstein
    Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, NY 11030, USA
    JAMA 293:1900-5. 2005
    ..Nesiritide improves symptoms in patients with acutely decompensated heart failure compared with placebo and appears to be safer than dobutamine. Its short-term safety relative to standard diuretic and vasodilator therapies is less clear...
  6. ncbi request reprint Increasing organ transplantation--fairly
    Jonathan D Sackner-Bernstein
    Division of Cardiology, North Shore University Hospital, Manhasset, NY 11030, USA
    Transplantation 77:157-9. 2004
    ..Such a system will encourage more donation as people on the donor list start to receive transplants themselves, especially when the transplant takes place quickly, before risk becomes excessive...
  7. ncbi request reprint Neurohormonal antagonism in heart failure: what is the optimal strategy?
    Jonathan D Sackner-Bernstein
    Division of Cardiology, St Luke s Roosevelt Hospital, New York, NY, USA
    Mt Sinai J Med 71:115-26. 2004
    ..Overall prognosis however remains poor. We review the data from these trials to encourage clinicians to use these proven neurohormonal antagonists in optimizing therapeutic strategy...
  8. ncbi request reprint Practical guidelines to optimize effectiveness of beta-blockade in patients postinfarction and in those with chronic heart failure
    Jonathan D Sackner-Bernstein
    Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, New York 11030, USA
    Am J Cardiol 93:69B-73B. 2004
    ..This article reviews the scientific evidence for the hierarchy of antiadrenergic agents and addresses practical issues associated with initiation of therapy and long-term management...
  9. ncbi request reprint Nesiritide for acute decompensated heart failure: does the benefit justify the risk?
    Jonathan Sackner-Bernstein
    Clinilabs, Inc, 423 West 55th Street, 4th Floor, New York, NY 10019, USA
    Curr Cardiol Rep 9:187-93. 2007
    ..We conclude that with nesiritide, the risks of therapy outweigh the benefits demonstrated to date...
  10. ncbi request reprint Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure
    Paul J Hauptman
    Division of Cardiology, Saint Louis University School of Medicine, St Louis, Missouri, USA
    Am J Cardiol 98:60L-66L. 2006
    ..The background, methods, and statistical approaches used in this trial are reviewed in this article...
  11. ncbi request reprint How should diuretic-refractory, volume-overloaded heart failure patients be managed?
    Jonathan D Sackner-Bernstein
    Division of Cardiology, St Luke s Roosevelt Hospital Center, New York, New York, USA
    J Invasive Cardiol 15:585-90. 2003
    ....
  12. ncbi request reprint New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients
    Jonathan D Sackner-Bernstein
    Heart Failure and Cardiomyopathy Center, Division of Cardiology, North Shore University Hospital, Manhasset, New York, USA
    Rev Cardiovasc Med 4:S25-9. 2003
    ..The COMET (Carvedilol or Metoprolol European Trial) study reinforces this view by establishing that beta-blockers are not simply interchangeable agents...
  13. ncbi request reprint Robotically assisted left ventricular epicardial lead implantation for biventricular pacing
    Joseph J Derose
    Division of Cardiothoracic Surgery, St Luke s Roosevelt Hospital Center and Columbia University College of Physicians and Surgeons, New York, New York, USA
    J Am Coll Cardiol 41:1414-9. 2003
    ..Ventricular resynchronization might be achieved in a minimally invasive fashion using a robotically assisted, direct left ventricular (LV) epicardial approach...
  14. ncbi request reprint Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction
    Gregg C Fonarow
    Rev Cardiovasc Med 4:S54-9. 2003